1
Chengbin Wu, Tariq Ghayur, Richard W Dixon, Jochen G Salfeld: Dual variable domain immunoglobulin and uses thereof. Abbott Laboratories, Tara Seshadri, Kenneth Zwicker, Yankwich & Associates P C, November 3, 2009: US07612181 (139 worldwide citation)

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.


2
Chengbin Wu, Tariq Ghayur, Richard W Dixon, Jochen G Salfeld: Dual variable domain immunoglobulin and uses thereof. Abbott Laboratories, Peter Dini, Yankwich & Associates P C, September 4, 2012: US08258268 (46 worldwide citation)

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.


3
Chengbin Wu, Richard W Dixon, Jonathan P Belk, Maria A Argiriadi, Hua Ying, Carolyn A Cuff, Terry L Melim, Shankar Kumar, Paul R Hinton, Yan Chen: Interleukin-13 binding proteins. Abbott Laboratories, Kenneth Zwicker, Stephen J Gaudet, Yankwich & Associates P C, March 29, 2011: US07915388 (35 worldwide citation)

The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention ca ...


4
Victor Bronshtein, Lynn Linkowski: Formulation of preservation mixtures containing sensitive biologicals to be stabilized for ambient temperature storage by drying. Quadrant Drug Delivery, Leon R Yankwich, Michael R Wesolowski, Yankwich & Associates P C, March 29, 2005: US06872357 (29 worldwide citation)

This invention relates to formulations and methods for preserving sensitive biologicals, viruses, bacteria and eukaryotic cells by drying. More particularly, the invention relates to preservation mixtures containing viruses or cells and protectants, including a combination of a methylated monosaccha ...


5
Victor Bronshtein, Kevin R Bracken, John G Cambell: Bulk drying and the effects of inducing bubble nucleation. Avant Immunotherapeutics, Yankwich & Associates P C, Leon R Yankwich, Michael R Wesolowski, April 26, 2005: US06884866 (22 worldwide citation)

The present invention discloses apparatus and methods of inducing bubble nucleation to overcome problems commonly associated with preservation by foam formation. Specifically, the invention relates to methods of using bubble nucleation in foam formation to preserve sensitive biological materials. Pr ...


6
Oliver Müller, Markus Sprenger Haussels, Helge Bastian, Stefanie Vollert: Method for isolating DNA from biological materials. Qiagen, Yankwich & Associates P C, Leon R Yankwich, Michael R Wesolowski, January 31, 2006: US06992182 (22 worldwide citation)

The invention relates to a method for the stabilization, purification or/and isolation of nucleic acids from biological materials, in particular stool samples which may contain contaminations and interfering substances. Furthermore, a reagent kit suitable for carrying out the method of the invention ...


7
Roy Curtiss III, Steven A Tinge: Recombinant bacterial vaccine system with environmentally limited viability. Washington University, Yankwich & Associates P C, Leon R Yankwich, Michael R Wesolowski, January 18, 2011: US07871604 (20 worldwide citation)

Disclosed is an Environmentally Limited Viability System (ELVS) for microorganisms based on temperature differences between permissive and non-permissive environments. Viability of the microorganisms are limited to the permissive environment by specifically expressing one or more essential genes onl ...


8
Norman Barras, Ian David Cox: Colon cleansing compositions and methods. Norgine Europe, Yankwich & Associates P C, Leon R Yankwich, Michael R Wesolowski, January 30, 2007: US07169381 (20 worldwide citation)

A composition comprising, per liter of aqueous solution, from 30 to 350 g polyethylene glycol, from 3 to 20 g of an ascorbic acid component selected form the group consisting of ascorbic acid, a salt of ascorbic acid, or a mixture thereof, an alkali metal or alkaline earth metal sulphate, preferably ...


9
Roy Curtiss III, Steven A Tinge: Regulated antigen delivery system (RADS). Washington University, AVANT Immunotherapeutics, Yankwich & Associates P C, Leon R Yankwich, Micahel R Wesolowski Esq, March 11, 2008: US07341860 (19 worldwide citation)

We describe a regulated antigen delivery system (RADS) that has (a) a vector that includes (1) a gene encoding a desired gene product operably linked to a control sequence, (2) an origin of replication conferring vector replication using DNA polymerase III, and (3) an origin of replication conferrin ...


10
Markus Sprenger Haussels: Nucleic acid isolation from stool samples and other inhibitor-rich biological materials. Qiagen, Leon R Yankwich, David G O Brien, Yankwich & Associates P C, February 28, 2006: US07005266 (18 worldwide citation)

The invention relates to a method for the stabilization, purification or/and isolation of nucleic acids from material samples, in particular, stool samples, which can contain impurities and inhibitors or interfering substances. The invention further relates to a reagent kit for carrying out said met ...